Emergent BioSolutions Inc.
Emergent BioSolutions Inc.（EBS）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · EBS · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
8
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Emergent BioSolutions Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
EBS 季度内部人买卖趋势
EBS 内幕交易卖出 · EBS 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · EBS CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
EBS 高管卖出股份 · EBS 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Apr 30, 2026 | Dayal Sujata Tyagi Director | Award | 25,344 | — | Form 4 |
| May 1, 2026 | Dayal Sujata Tyagi Director | Sale | 12,781 | $107K | Form 4 |
| May 1, 2026 | Dayal Sujata Tyagi Director | Sale | 980 | $9K | Form 4 |
| Apr 30, 2026 | DeGolyer Donald W Director | Award | 25,344 | — | Form 4 |
| May 1, 2026 | DeGolyer Donald W Director | Sale | 14,527 | $121K | Form 4 |
| May 1, 2026 | DeGolyer Donald W Director | Sale | 954 | $9K | Form 4 |
| Apr 30, 2026 | Katkin Keith Director | Award | 25,344 | — | Form 4 |
| Apr 30, 2026 | Katkin Keith Director | Sale | 15,481 | $128K | Form 4 |
| Apr 30, 2026 | White Marvin L Director | Award | 25,344 | — | Form 4 |
| Apr 30, 2026 | FOWLER JOHN D JR Director | Award | 25,344 | — | Form 4 |
| Apr 30, 2026 | Richard Ronald Director | Award | 25,344 | — | Form 4 |
| Apr 30, 2026 | Zoon Kathryn C Director | Award | 25,344 | — | Form 4 |
| May 1, 2026 | Zoon Kathryn C Director | Sale | 16,145 | $135K | Form 4 |
| May 1, 2026 | Zoon Kathryn C Director | Sale | 1,057 | $9K | Form 4 |
| Apr 30, 2026 | Fowler Neal Franklin Director | Award | 25,344 | — | Form 4 |
| Apr 30, 2026 | Harsanyi Zsolt Chairman · Director | Award | 25,344 | — | Form 4 |
| Apr 29, 2026 | Williams Paul Anthony SVP, Products Business | Award | 100,111 | — | Form 4 |
| Apr 29, 2026 | Lowry Simon C SVP, R&D, CMO | Award | 100,111 | — | Form 4 |
| Apr 29, 2026 | Glessner Coleen EVP, Quality & Ethics, and CPL | Award | 100,111 | — | Form 4 |
| Apr 29, 2026 | LINDAHL RICHARD S EVP, Chief Financial Officer | Award | 162,680 | — | Form 4 |
| Apr 29, 2026 | Perl Jessica SVP, General Counsel, Corp Sec | Award | 104,282 | — | Form 4 |
| Apr 29, 2026 | Hartzel William SVP, Bioservices | Award | 100,111 | — | Form 4 |
| Apr 29, 2026 | PAPA JOSEPH C President and CEO · Director | Award | 187,708 | — | Form 4 |
| Apr 1, 2026 | Williams Paul Anthony SVP, Products Business | Sale | 4,000 | $34K | Form 4 |
| Mar 5, 2026 | PAPA JOSEPH C President and CEO · Director | Other | 37,055 | $313K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 EBS 内幕交易
EBS 内幕交易
Emergent BioSolutions Inc.（EBS）内幕交易数据来源于公司内部人（包括LINDAHL RICHARD S (EVP, Chief Financial Officer), Hartzel William (SVP, Bioservices), DeGolyer Donald W (Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。EBS内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Emergent BioSolutions Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
EBS 内幕交易 · 5个问题Emergent BioSolutions Inc.（EBS）的内部人包括高管和董事，如LINDAHL RICHARD S (EVP, Chief Financial Officer), Hartzel William (SVP, Bioservices), DeGolyer Donald W (Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026